Collectively, our observations indicate that therapeutic modulation of peripheral GPR55 activity may provide a means for countering obesity-linked metabolic dysfunction and insulin resistance and improving the metabolic status of such tissues. The gene discussed is GPR55; the disease is obesity disorder.